As of December 27, 2023, a cadre of highly accurate Wall Street analysts has released the latest ratings for high-yield dividend stocks, revealing promising options within the healthcare sector. Among the standout picks are three stocks with enticing dividend yields, each presenting unique investment opportunities.
1. Organon & Co. (NYSE: OGN) – Dividend Yield: 7.93%
Organon & Co. takes the spotlight with an impressive dividend yield of 7.93%. Notably, the company has strategically positioned itself in the European market by securing exclusive distribution and promotion rights for Eli Lilly’s migraine medicines, Emgality (Galcanezumab), and Rayvow (Lasmiditan). This recent move is anticipated to bolster Organon’s future growth and profitability significantly.
2. Viatris Inc. (NASDAQ: VTRS) – Dividend Yield: 4.48%
Viatris Inc., with a commendable dividend yield of 4.48%, presents an attractive option for dividend-seeking investors. While slightly lower than Organon & Co., the company remains a compelling choice. The last ex-dividend date for Viatris Inc. was on November 22, 2023.
Analysts, including David Amsellem from Piper Sandler and Terence Flynn from Morgan Stanley, have conducted thorough evaluations of both Organon & Co. and Viatris Inc. These assessments provide valuable insights for investors seeking well-informed decisions.
These high-yield dividend stocks in the healthcare sector not only offer attractive returns but also exhibit promising growth potential. With solid dividend yields and positive analyst ratings, Organon & Co. and Viatris Inc. emerge as compelling considerations for investors looking to enhance their portfolios with reliable income streams.
